AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20090397
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) consisting of ten consecutive weekly sessions
Trial: 17678902
Drug: Oral desogestrel
RxNorm normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral desogestrel (n = 30) for 10 days combined with a tablet of raloxifene (60 mg) per vaginam (group A)
Trial: 17678902
Drug: Oral desogestrel
RxNorm normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral desogestrel at 60 mg/day (n = 30; group B)
Trial: 17678902
Drug: Oral danazol
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral danazol at 200 mg, three times a day (n = 30; group C)
Trial: 16236844
Drug: Inhaled nebulized
RxNorm normalized name: Hydra-Neb Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nebulized racemic glycopyrrolate (0.5, 1.0, and 2.0 mg)
Trial: 10543650
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of nonionic contrast material (300 mg I/mL) at 2 mL/s
Trial: 10543650
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of nonionic contrast material (300 mg I/mL) at 1.5 mL/s
Trial: 10543650
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of nonionic contrast material (300 mg I/mL) at 3 mL/s
Trial: 10543650
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of nonionic contrast material (300 mg I/mL) at 4 mL/s
Trial: 7762723
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccination (first dose)
Trial: 7762723
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccination (two doses)
Trial: 1702885
Drug: Gordox therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gordox therapy (2 M IU within 20 min after induction, followed by 0.5 M IU/hour infusion until end of operation)
Trial: 1702885
Drug: Gordox therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gordox therapy
Trial: 206826
Drug: Clofibate and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibate and beta-pyridylcarbinol (1.000 mg clofibrate and 50 mg beta-pyridylcarbinol per day)
Trial: 206826
Drug: Clofibate (1.500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibate (1.500 mg per day)
Trial: 9568752
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg daily plus cholestyramine 4 g daily
Trial: 7887103
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% wound infiltration (10 ml)
Trial: 10600086
Drug: Amprenavir 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir 1200 mg
Trial: 10600086
Drug: Amprenavir 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir 1200 mg plus Ketoconazole 400 mg
Trial: 8743497
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (0.58 g/kg body wt/day)
Trial: 8743497
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low protein diet (0.28 g/kg body wt/day supplemented with keto acids and amino acids)
Trial: 8743497
Drug: Usual protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual protein diet (1.3 g/kg body wt/day)
Trial: 28835586
Drug: ≤15 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≤15 mg/day additive tolvaptan (TLV)
Trial: 28835586
Drug: ≤40 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≤40 mg/day increased furosemide (FUR)
Trial: 26911639
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 1,600 mg once daily
Trial: 26911639
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 1,200 mg once daily
Trial: 24362944
Drug: Telaprevir (TVR)
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir (TVR) plus PEG‐IFN and ribavirin therapy
Trial: 24362944
Drug: Telaprevir (TVR)
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir (TVR) plus PEG‐IFN and ribavirin therapy with IFNL4 TT/TT genotype
Trial: 24362944
Drug: Telaprevir (TVR)
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir (TVR) plus PEG‐IFN and ribavirin therapy with IFNL4 TT/ΔG or ΔG/ΔG genotypes
Trial: 24362944
Drug: Telaprevir (TVR)
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir (TVR) at a reduced dose of 1,500 mg per day
Trial: 24362944
Drug: Younger patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Younger patients (≤65 years) receiving the same therapy
Trial: 17570908
Drug: Medication-free control
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-free control group
Trial: 15468027
Drug: Multiwavelength light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiwavelength light therapy (14 sessions, 3 times a week, energy used was 4.5 J/cm(2))
Trial: 15468027
Drug: Multiwavelength light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiwavelength light therapy (for stage 3 and 4 ulcers)
Trial: 15468027
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (control group for stage 3 and 4 ulcers)
Trial: 11696741
Drug: 5 mg.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg. oxybutynin orally
Trial: 11696741
Drug: Passive diffusion
RxNorm normalized name: LUNG DIFFUSION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive diffusion of 5 mg. oxybutynin intravesically
Trial: 11696741
Drug: Electromotive administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electromotive administration of 15 mg. oxybutynin
Trial: 8027416
Drug: Levodopa (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (up to 7 mg/kg per day) and Carbidopa (100 mg/day)
Trial: 8027416
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (four times a day)
Trial: 4348345
Drug: p-hydroxynorephedrine (PHN)
RxNorm normalized name: Hydroxynorephedrine
DrugBank: Metaraminol (DB00610)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: p-hydroxynorephedrine (PHN) 600 mg daily
Trial: 27633880
Drug: CRS +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CRS + HIPEC with lobaplatin 50 mg/m² and docetaxel 60 mg/m² in 6000 mL of normal saline at 43 ± 0.5 °C for 60 min
Trial: 18209013
Drug: FLIRI (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLIRI (irinotecan 180 mg/m(2) on day 1, 5‐FU 500 mg/m(2) and FA 60 mg/m(2) on day 1 and 2)
Trial: 18209013
Drug: Lv5FU2-IRI (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lv5FU2-IRI (irinotecan 180 mg/m(2) on day 1, FA 200 mg/m(2), 5‐FU bolus 400 mg/m(2) and infused 5‐FU 600 mg/m(2) on day 1 and 2)
Trial: 15180233
Drug: Early individualized
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early individualized postoperative occupational therapy (OT) program
Trial: 11281614
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (2 x 500 mg tablets daily)
Trial: 9885441
Drug: Response-oriented induction
RxNorm normalized name: Besponsa Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response-oriented induction therapy consisting of doxorubicin, vincristine, cyclophosphamide, L-asparaginase, and prednisolone.
Trial: 9885441
Drug: Response-oriented induction
RxNorm normalized name: Besponsa Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response-oriented induction therapy with intrathecal chemotherapy on day 8.
Trial: 9885441
Drug: Response-oriented induction
RxNorm normalized name: Besponsa Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response-oriented induction therapy without intrathecal chemotherapy on day 8.
Trial: 7994784
Drug: TUR +
RxNorm normalized name: Trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TUR + intravesical epirubicin (20 mg/40 ml, 30 times/2 years)
Trial: 23867958
Drug: Early inhaled
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early inhaled nitric oxide (iNO)
Trial: 21224020
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 10mg
Trial: 16373993
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of alpha-cyclodextrin (control)
Trial: 16373993
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of alpha-cyclodextrin
Trial: 16373993
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of alpha-cyclodextrin
Trial: 16373993
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of alpha-cyclodextrin
Trial: 16373993
Drug: alpha-cyclodextrin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-cyclodextrin (all doses)
Trial: 16373993
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of alpha-cyclodextrin
Trial: 15037882
Drug: Standard behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioral treatment with exercise level of 4186 kJ/week (1000 kcal/week)
Trial: 15037882
Drug: Standard behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioral treatment with exercise level of 10465 kJ/week (2500 kcal/week)
Trial: 10910003
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment (0.04 IU/kg) for 4 weeks
Trial: 9533345
Drug: 5% Amlexanox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Amlexanox oral paste (Aphthasol)
Trial: 8276984
Drug: Flurbiprofen, 50
RxNorm normalized name: Flurbiprofen, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen, 50 mg b.d. for 21 days
Trial: 8276984
Drug: Flurbiprofen, 50
RxNorm normalized name: Flurbiprofen, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen, 50 mg b.d. for 7 days (post-treatment)
Trial: 2882767
Drug: elixir preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elixir preparation of temazepam
Trial: 2882767
Drug: capsule preparation
RxNorm normalized name: bovine joint capsule preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule preparation of temazepam
Trial: 23929260
Drug: L-AGE meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-AGE meal (steamed)
Trial: 18334867
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) in addition to mebeverine
Trial: 15616772
Drug: FAM (chemotherapy)
RxNorm normalized name: fam-trastuzumab deruxtecan-nxki Injection [Enhertu]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAM (chemotherapy)
Trial: 11335732
Drug: Reduced osmolarity
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced osmolarity ORS solution
Trial: 9267272
Drug: Preemptive analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive analgesia with a combination of lidocaine hydrochloride and bupivacaine hydrochloride
Trial: 9267272
Drug: Preemptive analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive analgesia with saline solution
Trial: 3554125
Drug: Amoxicillin-clavulanate potassium
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate potassium
Trial: 30446405
Drug: One G
RxNorm normalized name: Arlatone G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One G (OG) files (Micro‐Mega, Besançon, France)
Trial: 29678195
Drug: Attention‐matched motor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention‐matched motor therapy
Trial: 22237688
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (G+MET)
Trial: 22237688
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (NPH+MET)
Trial: 19417734
Drug: Standard-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose tirofiban (0.4 microg x kg(‐1) x min(‐1) bolus for 30 min, followed by 0.10 microg x kg(‐1) x min(‐1) infusion for 36-48 h)
Trial: 19417734
Drug: Low-dose tirofiban
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tirofiban (0.4 microg x kg(‐1) x min(‐1) bolus for 30 min, followed by 0.075 microg x kg(‐1) x min(‐1) infusion for 36-48 h)
Trial: 22490713
Drug: Standard-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose tirofiban
Trial: 19417734
Drug: Low-dose tirofiban
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tirofiban
Trial: 17448840
Drug: Standardized surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized surgical and analgesic protocols
Trial: 11061578
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (200 mL double-strength three times a day for 3 days)
Trial: 9311179
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol (100 microgram tablets)
Trial: 9311179
Drug: Intracervical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical prostaglandin E2 gel (1.5 mg)
Trial: 8393389
Drug: Lisinopril therapy
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril therapy in subjects with high norepinephrine levels
Trial: 8393389
Drug: Lisinopril therapy
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril therapy in subjects with low norepinephrine levels
Trial: 2878272
Drug: Intrathecally administered
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecally administered natural human fibroblast interferon (IFN-B)
Trial: 29346838
Drug: BMS-962212 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-962212 (20 mg h-1)
Trial: 14996065
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.1% ointment under occlusion for 48 h
Trial: 14996065
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 0.1% ointment under occlusion for 48 h
Trial: 10626714
Drug: Ropivacaine 0.2%/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2%/2 microg x ml(‐1) fentanyl
Trial: 10626714
Drug: Bupivacaine 0.125%/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.125%/2 microg x ml(‐1) fentanyl
Trial: 9127122
Drug: Indobufen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen (200 mg/day)
Trial: 8233639
Drug: Pefloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin (400 mg q 12 h)
Trial: 8233639
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg q 12 h)
Trial: 8233639
Drug: Pefloxacin and
RxNorm normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin and Ofloxacin with Ketoprofen (100 mg daily)
Trial: 27044069
Drug: Participants who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who endorsed false beliefs about biological differences rated the black patient's pain as lower and made less accurate treatment recommendations.
Trial: 27044069
Drug: Participants who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who did not endorse false beliefs about biological differences rated the black patient's pain as higher.
Trial: 25558905
Drug: Multi-vitamin-mineral preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-vitamin-mineral preparation supplemented with 300 mg guarana (Ac)
Trial: 25558905
Drug: Caffeine supplement
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine supplement (C)
Trial: 25558905
Drug: Placebo supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplement (Pl)
Trial: 19560638
Drug: ST/G autografts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST/G autografts
Trial: 18575221
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% gel for 12 weeks
Trial: 18575221
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% gel for 6 weeks followed by tazarotene 0.1% cream for 6 weeks (switch therapy)
Trial: 12477620
Drug: ACE-I (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-I (5 mg of enalapril)
Trial: 8963482
Drug: Convulsofin (test)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convulsofin (test) tablets (2 tablets each containing 300 mg calcium valproate, 263.4 mg valproic acid)
Trial: 8963482
Drug: Convulsofin (test)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convulsofin (test) tablets
Trial: 8963482
Drug: ref.A (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ref.A (2 dragees each of 300 mg calcium valproate)
Trial: 8963482
Drug: ref.B (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ref.B (600 mg sodium valproate in liquid form)
Trial: 1785001
Drug: Intravesical chemo-
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical chemo- and immunotherapy
Trial: 1785001
Drug: Adjuvant prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant prophylactic treatments
Trial: 1785001
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of T1G3 cancer
Trial: 26469986
Drug: Rapid combination
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid combination antiretroviral therapy (ART) initiated by pregnant women
Trial: 21864886
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality integrative medicine (CM‐IM) including hypnosis, therapeutic massage, and healing touch with each cycle of chemotherapy
Trial: 21864886
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality integrative medicine (CM‐IM)
Trial: 21864886
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without CM‐IM
Trial: 17915642
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug (loxoprofen 60 mg tablets)
Trial: 17915642
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug (loxoprofen 60 mg tablets)
Trial: 15548972
Drug: Everolimus (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (3 mg/day) + Reduced-Dose Neoral (RDN)
Trial: 15548972
Drug: Everolimus (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (3 mg/day) + Full-Dose Neoral (FDN)
Trial: 11672943
Drug: Flunitrazepam 0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 0.16 mg (slow onset)
Trial: 11672943
Drug: Flunitrazepam 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 0.8 mg (fast onset)
Trial: 11672943
Drug: Flunitrazepam 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 0.25 mg (slow onset)